Results 41 to 50 of about 11,405 (213)

An Injectable Electroactive Hydrogel Engineered for Stable Bioelectronic Interfaces

Advanced Materials Interfaces, EarlyView.
Injectable electroconductive hydrogels enable soft, conformal, and stable bioelectronic interfaces for electroceutical therapies. A catechol‐modified hyaluronic acid/alginate/edge‐functionalized graphene platform combines wet adhesion, shear‐thinning injectability, tissue‐matched mechanics, and electrochemical functionality.
Ying Zhou, Peng Zheng, Beverley Cheung, Chien Yu Huang, Greg Ryder, Jonathan R Clark, D S Abdullah Al Maruf, Yi‐Hui Wu, Ming‐Dou Ker, Xufeng Huang, Gordon G Wallace, Xiao Liu   +11 more
wiley   +1 more source

Impacts on Histological Features and 11C-Methyl-L-methionine Uptake After “One-Shot” Administration with Bevacizumab Before Surgery in Newly Diagnosed Glioblastoma

Translational Oncology, 2019
BACKGROUND: Bevacizumab (BEV), an antiangiogenic agent, induces dramatic normalization of the tumor vasculature in glioblastoma. This study aimed to clarify how one-time administration of BEV changes histological features in glioblastoma and how ...
Takaaki Beppu, Yuichi Sato, Noriyuki Yamada, Kazunori Terasaki, Toshiaki Sasaki, Tamotsu Sugai, Kuniaki Ogasawara   +6 more
doaj   +1 more source

Engineering Microbial Particles for Next‐Generation Biomedical Platforms

Advanced Science, EarlyView.
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li, Yunjie Lu, Ziyan Huang, Jianjiang Chen, Yanbin Liu, Lei Qin, Chao Wang, Yumin Wu   +7 more
wiley   +1 more source

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma

BMC Cancer, 2019
Background Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). Methods Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective ...
Moire Cuncannon, Matthew Wong, Dasantha Jayamanne, Linxin Guo, Nicola Cove, Helen Wheeler, Michael Back   +6 more
doaj   +1 more source

A Review of Failure Modes and Safety Strategies of Lithium‐Ion Batteries from Materials to Systems

Advanced Science, EarlyView.
A cascade‐aware framework is presented for lithium‐ion battery safety, linking thermal runaway initiation, acceleration, runaway reaction, and propagation with material‐, cell/pack‐, and system‐level interventions. By integrating failure mechanisms, quantitative safety indicators, and staged interception strategies, this review highlights how safer ...
Jin Hyeok Yang, Jae Yoon Sung, Hyunji Kweon, Seohyun Kim, Byunghoon Kim, Jongsoon Kim, Junyoung Mun, Jung Ho Kim, Ki Jae Kim   +8 more
wiley   +1 more source

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer

BMC Cancer, 2020
Background First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side ...
Masaaki Miyo, Takeshi Kato, Takayuki Yoshino, Takeharu Yamanaka, Hideaki Bando, Hironaga Satake, Kentaro Yamazaki, Hiroya Taniguchi, Eiji Oki, Masahito Kotaka, Koji Oba, Yoshinori Miyata, Kei Muro, Yoshito Komatsu, Hideo Baba, Akihito Tsuji   +15 more
doaj   +1 more source

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study

Therapeutic Advances in Medical Oncology, 2021
Background: The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC).
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, Akihito Kawazoe, Yasutoshi Kuboki, Kohei Shitara, Takashi Kojima, Hiroya Taniguchi, Jun Watanabe, Itaru Endo, Takayuki Yoshino   +10 more
doaj   +1 more source

Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis

BMJ Open, 2021
Objective To assess the efficacy and safety of bevacizumab (BEV) in patients with glioma.Design Systematic review and meta-analysis.Participants Adults aged 18 years and above, whose histology was confirmed to be malignant glioma.Primary and secondary ...
Kai Wang, Jianxin Guo, Tianze Sun, Tianze Wang, Zhuojun Wu   +4 more
doaj   +1 more source

Circularity, Sustainability, and the Quality of Coffee Sold via Vending Machines: What Do Italian Consumers Prefer?

Agribusiness, EarlyView.
ABSTRACT Vending is an important sector in the daily lives of many people, and coffee is the most frequently consumed product in the European market. Like many other sectors, vending is responding to the challenge of sustainable development by taking various actions, such as offering increasingly ecologically sound coffee while maintaining/improving ...
Alberto Bertossi, Stefania Troiano, Francesco Marangon   +2 more
wiley   +1 more source

Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.

PLoS ONE, 2017
PurposeBevacizumab (BEV) has been used for ovarian cancer (OC) for years in Taiwan, but the associated data related to outcome is scant. This retrospective study reviewed patients with OC treated with BEV and analyzed their results.Patients and ...
Wei-Chun Chen, Jiantai Timothy Qiu, Chyong-Huey Lai, Huei-Jean Huang, Cheng-Tao Lin, Min-Yu Chen, Hung-Hsueh Chou, Kuan-Gen Huang, Ting-Chang Chang   +8 more
doaj   +1 more source